Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue
31.3.2026 14:00:00 CEST | Business Wire | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys.
Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/

Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales
Consumer Trust is Won or Lost at Login
For consumers, digital trust often begins at login. Yet, 57% reported problems accessing a website in the past year, and 68% abandoned or switched providers due to slow performance or complicated sign-up processes. When access feels too slow or intrusive, 33% switch to a competitor or abandon the attempt, while 36% delay engagement or look for alternative channels.
Consumers are not demanding speed at the expense of security. Forty-five percent say they prefer stronger security checks, even if sign-ups take longer, compared to 22% who favor faster access with lighter protections. Familiar safeguards help build confidence, with 69% saying multifactor authentication increases trust and 68% saying the same about passkeys. Still, only 16% say they clearly understand how companies collect and use their personal data.
AI Adoption Outpaces Trust
As organizations accelerate their use of generative AI, 93% of IT leaders say they are already using, deploying or planning AI initiatives. Yet consumer confidence has not kept pace: only 23% say they trust companies to use AI responsibly with their data, while 77% remain concerned about AI agents acting on their behalf online.
Trust Gaps Widen as Banking Pulls Ahead
The 2026 Digital Trust Index shows the gap between the most trusted sectors and the rest widening sharply. Banking stands out as the clear trusted sector at 57% (up from 44% in 2025), making it the only industry where more than two in five consumers feel comfortable sharing personal information online. Most other sectors continue to operate in a trust deficit, where the disconnect between what organizations believe they deliver and what users actually experience drives abandonment, time-consuming workarounds, and increased risk.
Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. Government services rank second at 40%, followed by healthcare at 35%. Trust declines sharply beyond these top sectors, with insurance (23%) and education (15%) forming a distant second tier. Consumer-facing industries score much lower, including retail (10%), social media (9%), entertainment (7%), and hospitality (6%), while news media (5%), logistics (4%), and automotive (3%) rank at the bottom. Overall, consumers place the greatest online trust in sectors responsible for managing sensitive personal data and essential services, while entertainment, media, and platform companies face lower confidence.
Friction Fuels Delays and Risk for Partners
For business partner users, access reliability directly affects project delivery and revenue. Onboarding remains inconsistent as only 22% receive login credentials immediately, and just 30% get full permissions on first access, creating delays that ripple across sales cycles and customer commitments. When official processes lag, risky workarounds emerge. Sixty-six percent admit to sharing or borrowing credentials, often because of slow provisioning, creating hidden security debt and increased breach risk.
IT Leaders See the Risk but Struggle to Close the Gap
The 2026 Digital Trust Index shows IT leaders recognize the importance of modern authentication. Eighty-seven percent say offering passkeys is important, yet only 49% currently do so. This gap represents both risk and opportunity as consumers expect stronger, seamless security.
“The 2026 Digital Trust Index shows that as AI adoption is accelerating, trust is struggling to keep pace,” said Danny DeVreeze, Vice President of Identity and Access Management at Thales. “When AI simply helps people work faster, confidence is high. But when AI starts acting autonomously and making decisions or interacting with systems on a user’s behalf, people begin asking harder questions about security, control, and accountability.”
Architecting Access as Business Strategy
The Digital Trust Index 2026 shows that identity and access management are commercial levers, not back-office functions. Trust improves when authentication and permissions are reliable, adaptive, and clearly explained. When they are slow or opaque, abandonment rises, credential sharing spreads, and revenue leaks. Organizations that modernize authentication, limit unnecessary data collection, provide permission visibility, and deploy AI transparently will be best positioned to compete in an increasingly digital and AI-driven economy.
Methodology
The research was conducted by Vanson Bourne in January–February 2026, surveying 14,300 consumers, 1,300 partner users and 200 IT decision makers across the USA, Canada, Mexico, Brazil, UK, France, Germany, Netherlands, the UAE, South Africa, Singapore, Japan and Australia.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.
The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies.
Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331668723/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom